169 related articles for article (PubMed ID: 37153732)
21. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells.
Xu L; Zhang L; Hu C; Liang S; Fei X; Yan N; Zhang Y; Zhang F
Int J Oncol; 2016 Mar; 48(3):1175-86. PubMed ID: 26781188
[TBL] [Abstract][Full Text] [Related]
22. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway.
Zheng A; Song X; Zhang L; Zhao L; Mao X; Wei M; Jin F
J Exp Clin Cancer Res; 2019 Jul; 38(1):305. PubMed ID: 31300015
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
24. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
25. Non-canonical Fzd7 signaling contributes to breast cancer mesenchymal-like stemness involving Col6a1.
Yin P; Bai Y; Wang Z; Sun Y; Gao J; Na L; Zhang Z; Wang W; Zhao C
Cell Commun Signal; 2020 Sep; 18(1):143. PubMed ID: 32894152
[TBL] [Abstract][Full Text] [Related]
26. piR-823 contributes to colorectal tumorigenesis by enhancing the transcriptional activity of HSF1.
Yin J; Jiang XY; Qi W; Ji CG; Xie XL; Zhang DX; Cui ZJ; Wang CK; Bai Y; Wang J; Jiang HQ
Cancer Sci; 2017 Sep; 108(9):1746-1756. PubMed ID: 28618124
[TBL] [Abstract][Full Text] [Related]
27. A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties.
Liu S; Sun Y; Hou Y; Yang L; Wan X; Qin Y; Liu Y; Wang R; Zhu P; Teng Y; Liu M
J Hematol Oncol; 2021 Oct; 14(1):178. PubMed ID: 34715882
[TBL] [Abstract][Full Text] [Related]
28. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
[TBL] [Abstract][Full Text] [Related]
29. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis.
Shen W; Zhang X; Tang J; Zhang Z; Du R; Luo D; Liu X; Xia Y; Li Y; Wang S; Yan S; Yang W; Xiang R; Luo N; Luo Y; Li J
Theranostics; 2021; 11(5):2297-2317. PubMed ID: 33500726
[No Abstract] [Full Text] [Related]
30. Transcriptional activation of FN1 and IL11 by HMGA2 promotes the malignant behavior of colorectal cancer.
Wu J; Wang Y; Xu X; Cao H; Sahengbieke S; Sheng H; Huang Q; Lai M
Carcinogenesis; 2016 May; 37(5):511-21. PubMed ID: 26964871
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of microRNA-190 inhibits migration, invasion, epithelial-mesenchymal transition, and angiogenesis through suppression of protein kinase B-extracellular signal-regulated kinase signaling pathway via binding to stanniocalicin 2 in breast cancer.
Sun G; Liu M; Han H
J Cell Physiol; 2019 Aug; 234(10):17824-17838. PubMed ID: 30993707
[TBL] [Abstract][Full Text] [Related]
32. MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway.
Zhang H; Cai K; Wang J; Wang X; Cheng K; Shi F; Jiang L; Zhang Y; Dou J
Stem Cells; 2014 Nov; 32(11):2858-68. PubMed ID: 25070049
[TBL] [Abstract][Full Text] [Related]
33. E2A Modulates Stemness, Metastasis, and Therapeutic Resistance of Breast Cancer.
López-Menéndez C; Vázquez-Naharro A; Santos V; Dubus P; Santamaría PG; Martínez-Ramírez Á; Portillo F; Moreno-Bueno G; Faraldo MM; Cano A
Cancer Res; 2021 Sep; 81(17):4529-4544. PubMed ID: 34145034
[TBL] [Abstract][Full Text] [Related]
34. Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Chen JH; Huang WC; Bamodu OA; Chang PM; Chao TY; Huang TH
BMC Cancer; 2019 Jun; 19(1):634. PubMed ID: 31248373
[TBL] [Abstract][Full Text] [Related]
35. Targeting Interleukin-11 Receptor-α Impairs Human Endometrial Cancer Cell Proliferation and Invasion In Vitro and Reduces Tumor Growth and Metastasis In Vivo.
Winship AL; Van Sinderen M; Donoghue J; Rainczuk K; Dimitriadis E
Mol Cancer Ther; 2016 Apr; 15(4):720-30. PubMed ID: 26846819
[TBL] [Abstract][Full Text] [Related]
36. LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2.
Song X; Zhang X; Wang X; Chen L; Jiang L; Zheng A; Zhang M; Zhao L; Wei M
J Cell Mol Med; 2020 Jan; 24(1):772-784. PubMed ID: 31736268
[TBL] [Abstract][Full Text] [Related]
37. PIR promotes tumorigenesis of breast cancer by upregulating cell cycle activator E2F1.
Suleman M; Chen A; Ma H; Wen S; Zhao W; Lin D; Wu G; Li Q
Cell Cycle; 2019 Nov; 18(21):2914-2927. PubMed ID: 31500513
[TBL] [Abstract][Full Text] [Related]
38. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
39. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
[TBL] [Abstract][Full Text] [Related]
40. Sinomenine hydrochloride suppresses the stemness of breast cancer stem cells by inhibiting Wnt signaling pathway through down-regulation of WNT10B.
Li X; Chen W; Huang L; Zhu M; Zhang H; Si Y; Li H; Luo Q; Yu B
Pharmacol Res; 2022 May; 179():106222. PubMed ID: 35413424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
